Press Releases

（Shanghai, China, September 29, 2025）– WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced that it has been awarded the “Industry Leading CDMO” for its exceptional service quality, robust technological capabilities, global footprint, and continuous empowerment of industry innovation at the China Innovative Drug Decade Glory Awards. This recognition not only highlights WuXi XDC’s industry-leading position but also affirms its end-to-end, integrated service capabilities.

The China Innovative Drug Decade Glory Awards were presented at the 5th China Healthcare Decision-Makers Conference (2025 CHDC), co-hosted by Beijing Pharmaceutical Health Technology Development Center and Pharmcube. The Awards are based on the full industry chain data of Pharmacube and include eight major awards. It aims to recognize outstanding achievements over the past decade and to set examples for the next decade of the Chinese innovative drug industry by honoring excellent companies, institutions, and major innovative performance that have played a leading role in the upgrading of the Chinese innovative drug industry. Among them, the “Industry Leading CDMO” award is comprehensively evaluated from multiple dimensions, including the contribution and business competitiveness of CDMO companies. It selects benchmark enterprises that empower Chinese pharmaceutical innovation with value-added services, promote the accelerated launch of Chinese innovative drugs with efficiency revolution, and reshape the global competitive landscape of innovative drugs.

Over the past decade, China’s innovative drug industry ecosystem has been significantly improved, and the division of labor within the industry chain has become more mature. Many CDMO companies, including WuXi XDC, have continuously promoted the mass launch of innovative drugs through efficient and high-quality services, reshaping the global competitive landscape of innovative drugs. Since our establishment, we have been committed to our vision of “Linking Innovation to Health”, providing global customers with integrated solutions from early discovery to commercial manufacturing. Moving forward, WuXi XDC will continue to enhance our technological innovation and service platforms, collaborate with industry partners, unlock the therapeutic potential of bioconjugates, build a more open, efficient, and win-win innovation ecosystem, and contribute to the next golden decade of the pharmaceutical industry.

About WuXi XDC

WuXi XDC Cayman Inc. (stock code: 2268.HK) is a globally recognized contract research, development, and manufacturing organization (CRDMO) specializing in bioconjugates. The company offers a wide range of innovative conjugation and payload-linker technologies to facilitate the development of next-generation antibody-drug conjugates (ADCs). Focused on early-stage research and development of ADCs and other bioconjugates, WuXi XDC offers comprehensive one-stop services from preclinical to commercial manufacturing. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: www.wuxixdc.com

WuXi XDC Contacts

Investor: wuxixdc.ir@wuxibiologics.com

Media: wuxixdc_pr@wuxibiologics.com

BD: wuxixdc_info@wuxibiologics.com